1. Home
  2. ENTX vs NCSM Comparison

ENTX vs NCSM Comparison

Compare ENTX & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • NCSM
  • Stock Information
  • Founded
  • ENTX 2010
  • NCSM 2006
  • Country
  • ENTX Israel
  • NCSM United States
  • Employees
  • ENTX 21
  • NCSM N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • NCSM Oilfield Services/Equipment
  • Sector
  • ENTX Health Care
  • NCSM Energy
  • Exchange
  • ENTX Nasdaq
  • NCSM Nasdaq
  • Market Cap
  • ENTX 82.2M
  • NCSM 76.3M
  • IPO Year
  • ENTX 2018
  • NCSM 2017
  • Fundamental
  • Price
  • ENTX $1.85
  • NCSM $46.52
  • Analyst Decision
  • ENTX Strong Buy
  • NCSM
  • Analyst Count
  • ENTX 1
  • NCSM 0
  • Target Price
  • ENTX $10.00
  • NCSM N/A
  • AVG Volume (30 Days)
  • ENTX 76.7K
  • NCSM 19.0K
  • Earning Date
  • ENTX 11-07-2025
  • NCSM 10-29-2025
  • Dividend Yield
  • ENTX N/A
  • NCSM N/A
  • EPS Growth
  • ENTX N/A
  • NCSM N/A
  • EPS
  • ENTX N/A
  • NCSM 4.71
  • Revenue
  • ENTX $166,000.00
  • NCSM $175,468,000.00
  • Revenue This Year
  • ENTX N/A
  • NCSM $9.11
  • Revenue Next Year
  • ENTX N/A
  • NCSM $7.13
  • P/E Ratio
  • ENTX N/A
  • NCSM $10.24
  • Revenue Growth
  • ENTX 191.23
  • NCSM 19.31
  • 52 Week Low
  • ENTX $1.50
  • NCSM $16.81
  • 52 Week High
  • ENTX $2.79
  • NCSM $51.49
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 42.76
  • NCSM 63.66
  • Support Level
  • ENTX $1.83
  • NCSM $40.99
  • Resistance Level
  • ENTX $2.22
  • NCSM $51.49
  • Average True Range (ATR)
  • ENTX 0.11
  • NCSM 3.22
  • MACD
  • ENTX -0.02
  • NCSM 0.51
  • Stochastic Oscillator
  • ENTX 9.52
  • NCSM 65.26

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About NCSM NCS Multistage Holdings Inc.

NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.

Share on Social Networks: